KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) EBT Margin (2016 - 2025)

Historic EBT Margin for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to 1461.25%.

  • Arbutus Biopharma's EBT Margin rose 116400.0% to 1461.25% in Q3 2025 from the same period last year, while for Sep 2025 it was 289.31%, marking a year-over-year increase of 8480900.0%. This contributed to the annual value of 1133.04% for FY2024, which is 7314700.0% down from last year.
  • Per Arbutus Biopharma's latest filing, its EBT Margin stood at 1461.25% for Q3 2025, which was up 116400.0% from 23.3% recorded in Q2 2025.
  • Over the past 5 years, Arbutus Biopharma's EBT Margin peaked at 23.3% during Q2 2025, and registered a low of 1472.89% during Q3 2024.
  • In the last 5 years, Arbutus Biopharma's EBT Margin had a median value of 665.03% in 2021 and averaged 686.0%.
  • Its EBT Margin has fluctuated over the past 5 years, first tumbled by -10412900bps in 2024, then skyrocketed by 11697600bps in 2025.
  • Over the past 5 years, Arbutus Biopharma's EBT Margin (Quarter) stood at 665.03% in 2021, then soared by 47bps to 351.19% in 2022, then crashed by -156bps to 900.33% in 2023, then grew by 12bps to 794.09% in 2024, then plummeted by -84bps to 1461.25% in 2025.
  • Its EBT Margin was 1461.25% in Q3 2025, compared to 23.3% in Q2 2025 and 1390.59% in Q1 2025.